Pharmacokinetics of Recombinant Human Coagulation Factor Ⅷ Preparations in Patients with Severe Hemophilia A.
10.19746/j.cnki.issn.1009-2137.2023.06.028
- Author:
Chuan-Ming LIN
1
;
Zou-Fang HUANG
1
;
Liu-Yan XIN
1
;
Lin LI
1
;
Xiang YANG
1
;
Ting LI
1
;
Yi-Jian CHEN
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China.
2. Department of Hematology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China,E-Mail：chenyj2005@163.com.
- Publication Type:Journal Article
- Keywords:
factor Ⅷ;
pharmacokinetics;
severe hemophilia A
- MeSH:
Adult;
Humans;
Middle Aged;
Blood Coagulation Factors;
Factor VIII/pharmacokinetics*;
Hemophilia A;
Hemorrhage;
Recombinant Proteins/pharmacokinetics*;
Adolescent;
Young Adult
- From:
Journal of Experimental Hematology
2023;31(6):1787-1790
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To calculate the pharmacokinetic parameters of recombinant human coagulation factor Ⅷ using myPKFiT in patients with severe hemophilia A, and provide an individualized treatment plan for patients.
METHODS:A total of 42 patients with severe hemophilia A who were treated with recombinant human coagulation factor Ⅷ were included from January 2021 to December 2021. myPKFiT was used to calculate the pharmacokinetic parameters of FⅧ, and the individualized treatment plan for hemophilia A patients was formulated.
RESULTS:The median age of 42 patients with severe hemophilia A was 31（16-50） years old, the average weight was 54.0±9.9 kg, the half-life of FⅧ was 12.05±1.6 h, the time to more than 1% of the baseline was 62.3±15.3 h, and the 0 bleeding rate after the guidance of myPKFiT was significantly increased from 39% to 49%, the Annual bleeding rate was reduced from 3.6±2.5 to 2.1±2.0, and the Annual joint bleeding rate was reduced from 3.2±2.2 to 1.9±0.9, all of which were statistically different (P<0.05).
CONCLUSION:Individualized therapy in patients with severe hemophilia A who were guided by myPKFiT assay of pharmacokinetics parameters can significantly reduce the annual bleeding rate and annual joint bleeding rate of patients.
